Company Overview of Boehringer Ingelheim Pharmaceuticals, Inc.
Boehringer Ingelheim Pharmaceuticals, Inc. offers human prescription medicines for the treatment of lung health, cardiovascular diseases, men's prostate health, and anti-viral therapy. Its products include angiotensin II receptor blocker Micardis tablets for cardiovascular causes; and COMBIVENT RESPIMAT, an inhaler for patients with chronic obstructive pulmonary disease; Flibanserin for the treatment of hypoactive sexual desire disorder in pre-menopausal women; SPIRIVA HandiHaler for the reduction of exacerbations in patients with obstructive pulmonary disease; pramipexole dihydrochloride tablets for Parkinson's disease; Pradaxa for the study on management of deep vein thrombosis and pulmona...
900 Ridgebury Road
P.O. Box 368
Ridgefield, CT 06877-0368
Founded in 1971
Key Executives for Boehringer Ingelheim Pharmaceuticals, Inc.
Director of Office of Diversity and Inclusion
Manager of Communications and Public Relations
Compensation as of Fiscal Year 2017.
Boehringer Ingelheim Pharmaceuticals, Inc. Key Developments
FDA Provides Full Approval to Boehringer Ingelheim's Praxbind
Apr 17 18
Boehringer Ingelheim announced that the U.S. Food and Drug Administration has provided full approval for Praxbind(idarucizumab), the specific reversal agent for Pradaxa (dabigatran etexilate mesylate). Praxbind is indicated for patients treated with Pradaxa when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures or in life-threatening or uncontrolled bleeding. The FDA granted accelerated approval to Praxbind in October 2015, with continued approval contingent upon results from the phase III RE-VERSE AD trial. The final results of RE-VERSE AD were published in the New England Journal of Medicine in July 2017, and showed that Praxbind immediately reversed the anticoagulant effect of Pradaxa. The majority of patients had complete reversal of anticoagulation within four hours as measured by ecarin clotting time (ECT 82%) or diluted thrombin time (dTT 99%). In the RE-VERSE AD study, no adverse safety signals were observed and there was a low rate of thrombotic events. In clinical studies, Praxbind has not shown a procoagulant effect. Healthcare providers should consider resuming anticoagulant therapy as soon as medically appropriate due to the risk of thrombosis associated with patients' underlying conditions.
FDA Grants Fast Track Designation to Nintedanib of Boehringer Ingelheim for the Treatment of Systemic Sclerosis with Associated Interstitial Lung Disease
Mar 19 18
Boehringer Ingelheim announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease (SSc-ILD). The FDA's Fast Track designation facilitates the development of new therapies that treat serious conditions and fulfill an unmet medical need in an effort to get treatments to those in need sooner. This designation is based on Boehringer Ingelheim's Investigational New Drug application (IND) of nintedanib for the treatment of SSc-ILD and the anticipated efficacy and safety data from SENSCIS™ (Safety and Efficacy of Nintedanib in Systemic SClerosIS), a double-blind, randomized, placebo-controlled global Phase III trial. This pivotal study is fully enrolled, including more than 520 patients from 32 countries. Systemic sclerosis, also known as scleroderma, is a rare disease characterized by the thickening and scarring of connective tissue of multiple organs in the body, typically affecting women between ages 25 and 55. Most people with the disease will develop some degree of lung scarring, or interstitial lung disease (ILD), which is the leading cause of death among people with systemic sclerosis. Nintedanib, which is marketed as Ofev®, is approved for a rare lung disease called idiopathic pulmonary fibrosis, or IPF, and has been shown to slow disease progression as measured by annual rate of decline in lung function. Because SSC-ILD and IPF share similarities in how the underlying lung scarring, or fibrosis, forms in people with the disease, Boehringer Ingelheim is evaluating the impact of nintedanib on SSC-ILD.
Boehringer Ingelheim Pharmaceuticals, Inc. Presents at Summit for Clinical Ops Executives, Feb-12-2018 through Feb-15-2018
Feb 10 18
Boehringer Ingelheim Pharmaceuticals, Inc. Presents at Summit for Clinical Ops Executives, Feb-12-2018 through Feb-15-2018. Venue: Hyatt Regency, 9801 International Dr, Orlanda, Florida, United States. Presentation Date & Speakers: Feb-13-2018, Débora Araujo, Associate Director, Site Budgets and Payments (US Group Head). Feb-14-2018, Débora Araujo, Associate Director, Site Budgets and Payments (US Group Head). Feb-15-2018, Hassan Kadhim, Business Consultant for Clinical Operations.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|